



DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration
SOUTHWEST REGION

414

9/24/97
JH

Office of the Regional
Food and Drug Director
7920 Elmbrook Drive, Suite 102
Dallas, TX 75247-4982
TELEPHONE: 214-655-8100
FACSIMILE: 214-655-8130

September 8, 1997

WARNING LETTER

**CERTIFIED MAIL
RETURN RECEIPT REQUESTED**

CFN #1722926
Facility ID #120329

William J. Gresco
Chief Executive Officer
Columbia Lea Regional Medical Center
5419 North Lovington Highway
P.O. Box 3000
Hobbs, New Mexico 88240

Dear Mr. Gresco:

Your facility was inspected on August 25, 1997 by a representative of the Food and Drug Administration. This inspection revealed that your facility failed to comply with certain parts of the Quality Standards for Mammography (Standards) as specified in Title 21, *Code of Federal Regulations (CFR)*, Part 900.12, as follows:

21 CFR900.12(a)(1)(ii)(A)&(B): The interpreting physician did not meet the requirement of being board certified by any of the approved boards or having two months full-time training in the interpretation of mammograms: [REDACTED]

The specific deficiency noted above appeared under the level 1 heading on your MQSA Facility Inspection Report, which was issued at the close of the inspection. This deficiency may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility.

In addition, your response should address the Level 2 noncompliances that were listed on the inspection report provided to you at the close of the inspection. These Level 2 noncompliances are:

September 8, 1997

21 CFR900.12(a)(1)(ii)(C): The interpreting physicians did not meet the initial training requirement of having 40 hours of continuing medical education in mammography:

21 CFR900.12(a)(1)(iii)(A)&(B): The interpreting physicians did not meet the requirement of having read and interpreted mammograms from the examinations of at least 240 patients in 6 months:

21 CFR900.12(a)(1)(iv)(A): The interpreting physicians did not meet the continuing experience requirement of having read and interpreted mammograms from an average of 40 patient examinations per month over 24 months:

It is your responsibility to ensure adherence to each requirement of the Mammography Quality Standards Act of 1992 (MQSA) and FDA's regulations. You are responsible for investigating and determining the causes of the deficiencies that the inspection identifies and promptly initiating permanent corrective actions.

If you fail to promptly correct these deficiencies, FDA may, without further notice, initiate regulatory action. Under MQSA, FDA may:

- ▶ **impose civil money penalties** on a facility of up to \$10,000 **for each failure** to substantially comply with, **or each day** of failure to substantially comply with, the Standards.
- ▶ **suspend or revoke a facility's FDA certificate** for failure to comply with the Standards.
- ▶ **seek an injunction in federal court** to prohibit any mammography activity that constitutes a serious risk to human health.

Please note that FDA regulations do not preclude a State from enforcing its own State mammography laws and regulations. In some cases, these requirements may be more stringent than FDA's. Therefore, when you plan your corrective actions, you should consider the more stringent State requirements.

Within 15 working days after receiving this letter, you should notify FDA in writing of:

- ▶ the specific steps you have taken to **correct** the violations noted in this letter;
- ▶ each step your facility is taking to **prevent the recurrence** of similar violations;

If your facility is unable to complete the corrective action within 15 working days, you should state the reason for the delay and the time within which the corrections will be completed.

Page 3

September 8, 1997

Please send the original copy of your response to Deborah M. McGee, Radiation Specialist, Food and Drug Administration, 7920 Elmbrook Drive, Suite 102, Dallas, Texas 75247-4982.

If you have any questions regarding this letter or how to ensure you are meeting MQSA standards, please call Ms. McGee at 214-655-8100, extension 138.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Edward R. Esparza". The signature is stylized with a large, looped "E" and a cursive "Esparza".

Edward R. Esparza
Regional Food and Drug Director